Intuitive Surgical (NASDAQ:ISRG) Director Craig Barratt Sells 2,193 Shares

Intuitive Surgical, Inc. (NASDAQ:ISRG) Director Craig Barratt sold 2,193 shares of the firm’s stock in a transaction that occurred on Friday, October 24th. The shares were sold at an average price of $548.01, for a total transaction of $1,201,785.93. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Intuitive Surgical Price Performance

NASDAQ ISRG opened at $551.25 on Tuesday. Intuitive Surgical, Inc. has a 12 month low of $425.00 and a 12 month high of $616.00. The firm has a market capitalization of $197.61 billion, a PE ratio of 72.92, a P/E/G ratio of 5.02 and a beta of 1.61. The company’s 50 day simple moving average is $459.49 and its 200 day simple moving average is $497.31.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings data on Tuesday, October 21st. The medical equipment provider reported $2.40 EPS for the quarter, beating analysts’ consensus estimates of $1.99 by $0.41. Intuitive Surgical had a net margin of 28.58% and a return on equity of 15.08%. The business had revenue of $2.51 billion for the quarter, compared to analyst estimates of $2.41 billion. During the same quarter last year, the business earned $1.84 earnings per share. The business’s revenue for the quarter was up 22.9% on a year-over-year basis. Sell-side analysts anticipate that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on ISRG shares. Robert W. Baird set a $655.00 target price on shares of Intuitive Surgical in a report on Wednesday, October 22nd. Truist Financial set a $620.00 target price on shares of Intuitive Surgical and gave the stock a “buy” rating in a report on Wednesday, October 22nd. Hsbc Global Res upgraded shares of Intuitive Surgical to a “strong-buy” rating in a report on Thursday, October 23rd. HSBC raised their target price on shares of Intuitive Surgical from $595.00 to $644.00 and gave the stock a “buy” rating in a report on Thursday, October 23rd. Finally, Evercore ISI reduced their target price on shares of Intuitive Surgical from $535.00 to $450.00 and set an “in-line” rating for the company in a report on Tuesday, October 7th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $603.38.

Hedge Funds Weigh In On Intuitive Surgical

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Chilton Capital Management LLC boosted its stake in shares of Intuitive Surgical by 614.3% during the 1st quarter. Chilton Capital Management LLC now owns 50 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 43 shares during the period. Tobam boosted its stake in shares of Intuitive Surgical by 666.7% during the 2nd quarter. Tobam now owns 46 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 40 shares during the period. Elite Financial Inc. acquired a new stake in shares of Intuitive Surgical during the 1st quarter valued at $26,000. Kilter Group LLC acquired a new stake in shares of Intuitive Surgical during the 2nd quarter valued at $27,000. Finally, LFA Lugano Financial Advisors SA acquired a new stake in shares of Intuitive Surgical during the 1st quarter valued at $30,000. Institutional investors and hedge funds own 83.64% of the company’s stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.